Table 2.
Laboratory data and treatments of the patients with NMOSD.
| Acute phase | Remission | p-values | |
|---|---|---|---|
| Blood Tests | |||
| White Blood Cells (/μL) | 7223 ± 2187 | 7499 ± 3132 | 0.912 |
| Neutrophils (/μL) | 5138 ± 2169 | 4803 ± 2735 | 0.849 |
| Lymphocytes (/μL) | 1420 ± 639 | 2019 ± 1527 | 0.364 |
| Monocytes (/μL) | 544 ± 354 | 548 ± 253 | 0.983 |
| Albumin (g/dL) | 4.2 ± 0.4 | 3.8 ± 0.6 | 0.807 |
| CRP (mg/dL) | 0.367 ± 0.666 | 0.199 ± 0.485 | 0.410 |
| Cerebrospinal fluid test | |||
| Cell count (/mm3) | 13.7 ± 28.7 | 3.0 ± 3.0 | 0.621 |
| Protein (mg/dL) | 46.8 ± 37.4 | 36.6 ± 20.7 | 0.144 |
| Treatments at blood collection | |||
| None | 10 (47.6%) | 8 (38.1%) | |
| Steroids | 6 (28.6%) | 6 (28.6%) | |
| Immunosuppressants | 1 (4.8%) | 2 (9.5%) | |
| Steroids + Immunosuppressants | 3 (14.3%) | 4 (19.0%) | |
| Plasma exchange | 1 (4.8%) | 1 (4.8%) | |
Data are shown as mean ± standard deviation. CRP, C-reactive protein; NMOSD, neuromyelitis optica spectrum disorders.